Vasomune Therapeutics, Inc.

Vasomune to Present Late-Breaking Data on AV-001's Protective Effects Against COVID-19 at ATS Conference

16 days ago

• Vasomune Therapeutics will present late-breaking research showing how their lead candidate AV-001 protects against endothelial cell permeability induced by SARS-CoV-2 infection at the 2025 American Thoracic Society Conference. • AV-001, a first-in-class synthetic peptide targeting the Tie2 receptor, has demonstrated potential to normalize vascular function by enhancing endothelial stability and blocking vascular leak in preclinical studies. • The company continues to advance a Phase 2a study of AV-001 in patients with bacterial and viral pneumonia, addressing the critical role of vascular dysfunction in acute respiratory distress syndrome.